IMNM
Immunome, Inc.
$22.44
+1.13%
2026-05-08
About Immunome, Inc.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Key Fundamentals
Forward P/E
-10.49
EPS (TTM)
$-2.43
ROE
-52.1%
Revenue Growth (YoY)
-100.0%
Profit Margin
0.0%
Debt/Equity
0.61
Price/Book
3.95
Beta
2.12
Market Cap
$2.51B
Avg Volume (10D)
824K
Recent Breakout Signals
No recent breakout signals detected for IMNM.
Recent Price Range (60 Days)
60D High
$24.90
60D Low
$19.16
Avg Volume
1.1M
Latest Close
$22.44
Get breakout alerts for IMNM
Sign up for Breakout Scanner to receive daily notifications when IMNM triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Immunome, Inc. (IMNM) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IMNM daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IMNM operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.